An unbiased algorithm for objective separation of Alzheimer's, Alzheimer's mixed with cerebrovascular symptomology, and healthy controls from one another using electrovestibulography (EVestG)
- PMID: 35102489
- DOI: 10.1007/s11517-022-02507-1
An unbiased algorithm for objective separation of Alzheimer's, Alzheimer's mixed with cerebrovascular symptomology, and healthy controls from one another using electrovestibulography (EVestG)
Abstract
Diagnosis of Alzheimer's disease (AD) from AD with cerebrovascular disease pathology (AD-CVD) is a rising challenge. Using electrovestibulography (EVestG) measured signals, we develop an automated feature extraction and selection algorithm for an unbiased identification of AD and AD-CVD from healthy controls as well as their separation from each other. EVestG signals of 24 healthy controls, 16 individuals with AD, and 13 with AD-CVD were analyzed within two separate groupings: One-versus-One and One-versus-All. A multistage feature selection process was conducted over the training dataset using linear support vector machine (SVM) classification with 10-fold cross-validation, k nearest neighbors/averaging imputation, and exhaustive search. The most frequently selected features that achieved highest classification performance were selected. 10-fold cross-validation was applied via a linear SVM classification on the entire dataset. Multivariate analysis was run to test the between population differences while controlling for the covariates. Classification accuracies of ≥ 80% and 78% were achieved for the One-versus-All classification approach and AD versus AD-CVD separation, respectively. The results also held true after controlling for the effect of covariates. AD/AD-CVD participants showed smaller/larger EVestG averaged field potential signals compared to healthy controls and AD-CVD/AD participants. These characteristics are in line with our previous study results.
Keywords: Alzheimer’s Disease; Cerebrovascular pathology; Classification; Electrovestibulography; Feature selection.
© 2022. International Federation for Medical and Biological Engineering.
Similar articles
-
Evaluating the Diagnostic Value of Electrovestibulography (EVestG) in Alzheimer's Patients with Mixed Pathology: A Pilot Study.Medicina (Kaunas). 2023 Nov 28;59(12):2091. doi: 10.3390/medicina59122091. Medicina (Kaunas). 2023. PMID: 38138194 Free PMC article.
-
Physiological separation of Alzheimer's disease and Alzheimer's disease with significant levels of cerebrovascular symptomology and healthy controls.Med Biol Eng Comput. 2021 Aug;59(7-8):1597-1610. doi: 10.1007/s11517-021-02409-8. Epub 2021 Jul 15. Med Biol Eng Comput. 2021. PMID: 34263439
-
Baseline Prediction of rTMS efficacy in Alzheimer patients.Psychiatry Res. 2022 Feb;308:114348. doi: 10.1016/j.psychres.2021.114348. Epub 2021 Dec 20. Psychiatry Res. 2022. PMID: 34952254
-
Frontiers for the Early Diagnosis of AD by Means of MRI Brain Imaging and Support Vector Machines.Curr Alzheimer Res. 2016;13(5):509-33. doi: 10.2174/1567205013666151116141705. Curr Alzheimer Res. 2016. PMID: 26567735 Review.
-
Preemptive Diagnosis of Alzheimer's Disease in the Eastern Province of Saudi Arabia Using Computational Intelligence Techniques.Comput Intell Neurosci. 2022 Aug 23;2022:5476714. doi: 10.1155/2022/5476714. eCollection 2022. Comput Intell Neurosci. 2022. PMID: 36052046 Free PMC article. Review.
Cited by
-
Gray and White Matter Voxel-Based Morphometry of Alzheimer's Disease With and Without Significant Cerebrovascular Pathologies.Neurosci Insights. 2024 Jan 31;19:26331055231225657. doi: 10.1177/26331055231225657. eCollection 2024. Neurosci Insights. 2024. PMID: 38304550 Free PMC article.
-
Evaluating the Diagnostic Value of Electrovestibulography (EVestG) in Alzheimer's Patients with Mixed Pathology: A Pilot Study.Medicina (Kaunas). 2023 Nov 28;59(12):2091. doi: 10.3390/medicina59122091. Medicina (Kaunas). 2023. PMID: 38138194 Free PMC article.
-
Surface Versus Penetrative rTMS Stimulation May Be More Effective for AD Patients with Cerebrovascular Disease.Neurosci Insights. 2025 Mar 25;20:26331055251328355. doi: 10.1177/26331055251328355. eCollection 2025. Neurosci Insights. 2025. PMID: 40143889 Free PMC article.
References
-
- Elahi FM, Miller BL (2017) A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol 13:457–477. https://doi.org/10.1038/nrneurol.2017.96 - DOI - PubMed - PMC
-
- McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269. https://doi.org/10.1016/j.jalz.2011.03.005 - DOI - PubMed - PMC
-
- Turner RS, Stubbs T, Davies DA, Albensi BC (2020) Potential new approaches for diagnosis of Alzheimer’s disease and related dementias. Front Neurol 11:496. https://doi.org/10.3389/fneur.2020.00496 - DOI - PubMed - PMC
-
- Jack CR, Bennett DA, Blennow K et al (2018) NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia 14:535–562. https://doi.org/10.1016/j.jalz.2018.02.018 - DOI
-
- Wilczyńska K, Waszkiewicz N (2020) Diagnostic utility of selected serum dementia biomarkers: amyloid β-40, amyloid β-42, Tau protein, and YKL-40: a review. J Clin Med 9:3452. https://doi.org/10.3390/jcm9113452 - DOI - PMC
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical